Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2215/CJN.06540810 http://scihub22266oqcxt.onion/10.2215/CJN.06540810 21233458!3069366!21233458     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+J+Am+Soc+Nephrol 2011 ; 6 (4): 753-9 Nephropedia Template TP {{tp|p=21233458|t=2011. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent |pdf=|usr=}}{{21233458}} gab.com Text Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent JO: Clin J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=21233458 #FOAvip BACKGROUND AND OBJECTIVES: Acute infusion of the potent V2 receptor agonist 1-desamino-8-d-arginine vasopressin (dDAVP) reduces sodium excretion in humans, through an effect attributed to the stimulation of the amiloride sensitive epithelial sodium channel, ENaC, in ex vivo/in vivo experiments. We investigated in humans whether the antinatriuretic effect of dDAVP is sensitive to amiloride, a specific blocker of ENaC. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Forty-eight healthy normotensive adult men were assigned to a high Na/low K (250/40 mmol/d) diet, to suppress aldosterone secretion. dDAVP (4-mug intravenous bolus followed by 4 mug over 2 hours) was administrated before and after a 7-day administration of 20 mg/d amiloride. Urine and blood samples were collected before and at the end of the dDAVP infusion, to measure Na, K, creatinine, and osmolality concentrations. RESULTS: dDAVP alone decreased the urinary flow rate by 75% and the sodium excretion rate by 19% despite an increase in creatinine clearance by 38 ml/min. Potassium excretion rate was unchanged and the urinary Na/K ratio decreased by 18%. Seven-day amiloride administration had no effect on the dDAVP-induced decrease in the urinary flow rate (-71%) nor on the dDAVP-induced increase in creatinine clearance (+35 ml/min), but it fully prevented the dDAVP-induced decrease in both urinary sodium excretion (+1%) and urinary Na/K ratio (+21%). CONCLUSIONS: The antinatriuretic effect of dDAVP in humans is amiloride sensitive, and thus is related to the stimulatory effect on ENaC-mediated sodium reabsorption. This test provides a new tool to investigate ENaC function in a clinical setting. Twit Text FOAVip Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent ????Clin J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=21233458 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=21233458 #FOAvip English Wikipedia <ref>{{Cite pmid|21233458}}</ref> Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent #MMPMID21233458 Blanchard A; Frank M; Wuerzner G; Peyrard S; Bankir L; Jeunemaitre X; Azizi M Clin J Am Soc Nephrol 2011[Apr]; 6 (4): 753-9 PMID21233458show ga BACKGROUND AND OBJECTIVES: Acute infusion of the potent V2 receptor agonist 1-desamino-8-d-arginine vasopressin (dDAVP) reduces sodium excretion in humans, through an effect attributed to the stimulation of the amiloride sensitive epithelial sodium channel, ENaC, in ex vivo/in vivo experiments. We investigated in humans whether the antinatriuretic effect of dDAVP is sensitive to amiloride, a specific blocker of ENaC. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Forty-eight healthy normotensive adult men were assigned to a high Na/low K (250/40 mmol/d) diet, to suppress aldosterone secretion. dDAVP (4-mug intravenous bolus followed by 4 mug over 2 hours) was administrated before and after a 7-day administration of 20 mg/d amiloride. Urine and blood samples were collected before and at the end of the dDAVP infusion, to measure Na, K, creatinine, and osmolality concentrations. RESULTS: dDAVP alone decreased the urinary flow rate by 75% and the sodium excretion rate by 19% despite an increase in creatinine clearance by 38 ml/min. Potassium excretion rate was unchanged and the urinary Na/K ratio decreased by 18%. Seven-day amiloride administration had no effect on the dDAVP-induced decrease in the urinary flow rate (-71%) nor on the dDAVP-induced increase in creatinine clearance (+35 ml/min), but it fully prevented the dDAVP-induced decrease in both urinary sodium excretion (+1%) and urinary Na/K ratio (+21%). CONCLUSIONS: The antinatriuretic effect of dDAVP in humans is amiloride sensitive, and thus is related to the stimulatory effect on ENaC-mediated sodium reabsorption. This test provides a new tool to investigate ENaC function in a clinical setting. |Adult[MESH] |Amiloride/*pharmacology[MESH] |Deamino Arginine Vasopressin/*pharmacology[MESH] |Epithelial Sodium Channels/*physiology[MESH] |Humans[MESH] |Male[MESH] |Natriuretic Agents/*pharmacology[MESH] |Potassium, Dietary/administration & dosage[MESH] |Receptors, Vasopressin/physiology[MESH] |Sodium, Dietary/administration & dosage[MESH]Antinatriuretic effect of vasopressin in humans is amiloride sensitive(epmc).pdf DeepDyve Pubget Overpricing